Bravecto Plus spot-on for cats provides 3 months flea and tick protection plus a comprehensive worm treatment in a single spot-on.
Why choose Bravecto Plus for your cat:
Bravecto contains fluralaner.
Bravecto Plus spot-on solution* should be administered in accordance with the following (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight + 2 – 4.7 moxidectin/kg body weight):
Bodyweight (kg) of cat
Small (1.2 – 2.8kgs) 0.4 mL/pipette
Medium (> 2.8 – 6.25kgs) 0.89 mL/pipette
Large (> 6.25 – 12.5kgs) 1.79 mL/pipette
*For use in cats from 9 weeks of age and over 1.2kg.
For optimal control of tick and flea infestation, the Bravecto Plus * should be administered at 3 monthly intervals. Bravecto Plus* can be administered all year round.
1 x single dose packs
No adverse reactions were observed following topical administration to kittens aged 9-13 weeks and weighing 1.2-1.5 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Mild and transient skin reactions at the application site may be seen such as flaking skin, itching or hair loss. Shortly after application, the following signs were observed in clinical trials, but were uncommon: breathing discomfort after licking the application site, vomiting, vomiting of blood, diarrhoea, lethargy, hypersalivation, fever, rapid breathing, and dilated pupils.
Fluralaner is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence, itching and very rarely neurological signs including tremors, ataxia and seizures. Most adverse reactions are self-limiting and of short duration. If you have any concerns, please speak to your veterinarian.
If hypersensitivity to the active substance or to any of the excipients is known or suspected, do not use this product.
The safety has not been established in kittens less than 9 weeks old and/or cats weighing less than 1.2 kg. The safety has not been established for treatment with this product when administered at intervals shorter than 8 weeks. The safety of the product has not been established during pregnancy and lactation.